What's interesting is Pope, being the majority shareholder, also owns the rights to the U.S. gene therapy product of Introgen (INGNQ) and are now trying to claim Gendicine
So someone sees value in it. What happens to BPMA commons next I wish I knew
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.